A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3

Neurology

Volumn 78, Issue 8, 2012, Pages 545-550

  Zesiewicz, T A ^a   Greenstein, P E ^c   Sullivan, K L ^a   Wecker, L ^b   Miller, A ^a   Jahan, I ^a   Chen, R ^a   Perlman, S L ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GAIT; HUMAN; MALE; MOOD; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TINGLING; SMOKING CESSATION; SPINOCEREBELLAR DEGENERATION; STANDING; VIVID DREAM; WALKING;

EID: 84858129653     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318247cc7a     Document Type: Article

References (10)

1. Manto M, Marmolino D. Cerebellar ataxias. Curr Opin Neurol 2009;22:419-429.
2. Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 2009;10:191-193.
3. Zesiewicz TA, Sullivan KL. Treatment of ataxia and imbalance with varenicline (Chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clin Neuropharmacol 2008;31:363-365.
4. Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline Chantix: report of a patient with fragile X tremor/ataxia syndrome. Acta Neurol Scand 2009;119:135-138.
5. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010;74:839-845.
6. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-994. (Pubitemid 46227486)
7. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316 -325.
8. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801- 805.
9. Nakamizo T, Kawamata J, Yamashita H, et al. Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochem Biophys Res Commun 2005;330:1285-1289.
10. US Food and Drug Administration (FDA). Drug safety newsletter [online]. Available at: http://www.fda.gov/ Drugs/DrugSafety/DrugSafetyNewsletter/ ucm107311.htm. Accessed September 14, 2011.